Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | KARS1 | Q15046 | 8/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.36 |
| ▸ | CLK2 | P49760 | 3/20 | 0.36 |
| ▸ | CLK3 | P49761 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776077 | 0.90 | DYRK1A (0.35) | KARS1DYRK1ARAF1BRAFWNT1 | |
| SCHEMBL16776025 | 0.88 | CYP11B2 (0.38) | DYRK1ACLK2CLK3 | |
| SCHEMBL16776147 | 0.88 | KARS1 (0.35) | KARS1DYRK1ACLK2CLK3 | |
| SCHEMBL16776000 | 0.87 | PRKCI (0.39) | KARS1CNR1 | |
| SCHEMBL16776194 | 0.86 | FGFR4 (0.42) | PRKD3PRKD1PRKD2KARS1CNR1 | |
| SCHEMBL16776011 | 0.84 | CA9 (0.38) | CNR1 | |
| SCHEMBL16776171 | 0.84 | KARS1 (0.48) | PRKD3PRKD1PRKD2KARS1DYRK1A | |
| SCHEMBL16776185 | 0.84 | HTR2C (0.40) | DYRK1A | |
| SCHEMBL16775916 | 0.83 | FAAH (0.38) | CNR1 | |
| SCHEMBL16775826 | 0.82 | CA2 (0.40) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PRKD3 1969/4885PRKD1 2346/4885PRKD2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.